02.05.26 -- Where Innovation Meets Biomanufacturing Excellence

NGS provides a rapid, highly sensitive method for verifying biological product integrity. This technology replaces traditional, time-consuming assays with comprehensive genomic analysis, ensuring safety.

Partnering with a CDMO that demonstrates innovative and commercially validated cell line development capabilities is essential to protecting your market and securing investor support.

Transforming the CDMO experience means treating your molecule's journey from development to commercial supply with unmatched expertise, world-class facilities, and a flexible, quality-driven partnership.

With decades of experience, we offer a flexible and collaborative partnership model for manufacturing excellence that enables our clients to increase speed to market with full regulatory confidence.

Michael Brotz provides an in-depth look at our Seattle site and the unique capabilities of the facility, including its single-use and stainless-steel capacity, new manufacturing lines, and more.

This session provides a comprehensive overview of our biopharmaceutical contract manufacturing services for mammalian cell culture and microbial technologies.

Achieve greater agility and resilience in biopharma operations by implementing strategic resource optimization, which can generate millions in savings by reducing waste and maximizing the value of existing assets.

This philosophy is designed to overcome capacity constraints, regulatory complexities, and geopolitical risks to deliver unmatched scale, speed, supply chain agility, and resilience.

Leveraging cross-functional coordination between sites, harmonized tech transfers, one quality system, and synchronized team activities can streamline regulatory submissions and deliver high-quality commercial outcomes.

High-speed labeling systems boost accuracy, efficiency, and reliability to meet demanding pharmaceutical and vaccine production needs.

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

By leveraging our proprietary non-viral gene insertion technology, we ensure rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

Unlock the potential of your antibody-drug conjugate development by partnering with our experts in bioconjugation to ensure the efficacy, safety, and scalability of your innovative therapies.